Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Nutrient stimulation of enteroendocrine L cells induces the release of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1). The vagus nerve innervates visceral organs and may contribute to the mediation of gut-derived GLP-1’s effects on food intake, energy homeostasis, and glycemic control. To test the hypothesis that vagal afferent neuron (VAN) GLP-1 receptors (GLP-1Rs) are necessary for these effects of endogenous GLP-1, we established a novel bilateral nodose ganglia injection technique to deliver a lentiviral vector and to knock down VAN GLP-1Rs in male Sprague Dawley rats. We found that a full expression of VAN GLP-1Rs is not necessary for the maintenance of long-term energy balance in normal eating conditions. VAN GLP-1R knockdown (kd) did, however, increase meal size and accelerated gastric emptying. Moreover, postmeal glycemia was elevated and insulin release was blunted in GLP-1R kd rats, suggesting that VAN GLP-1Rs are physiological contributors to the neuroincretin effect after a meal. Collectively, our results highlight a crucial role for the VANs in mediating the effects of endogenous GLP-1 on food intake and glycemia and may promote the further development of GLP-1–based therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs can exert their local effects by activating vagal dendritic terminals that innervate the gut.418–420”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [418]
In the citing paper
“Peripheral GLP-1/GLP-1RAs may also interact with the CNS indirectly by GLP-1R expressed on vagal afferent fibers, signaling via nodose ganglia (57) to the nucleus tractus solitarii within the brainstem.”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [57]
In the citing paper
“Importantly, knockdown of GLP-1R in VANs increased meal size (39), and abolished the satiating effects of secretagogue-induced GLP-1 release (34).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [39]
In the citing paper
“Given the role of GLP-1R-expressing VANs in physiological satiation (23, 39)”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [39]
Citations
Cites
Functional and chemical anatomy of the afferent vagal system
Berthoud, H.-R., & Neuhuber, W. L. (2000) · Autonomic Neuroscience · doi:10.1016/s1566-0702(00)00215-0 · Cited by 1,280 · cited 13×
“We measured HPV blood glucose in the fasted and fed conditions in control and GLP-1R kd rats.”
BackgroundInfluentialSensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
Erickson, J. C., Clegg, K. E., & Palmiter, R. D. (1996) · Nature · doi:10.1038/381415a0 · Cited by 1,008 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 2×
“Recent studies, however, have shown that GLP-1R agonists, such as liraglutide, exert their body weight and glucose-lowering effects independent of vagal afferents (45) and do not require VAN GLP-1Rs (17).”
BackgroundAbbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodVagal Sensory Neuron Subtypes that Differentially Control Breathing
Chang, R. B., Strochlic, D. E., Williams, E. K., Umans, B. D., & Liberles, S. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.022 · Cited by 439 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Qian, S., Chen, H., Weingarth, D., Trumbauer, M. E., Novi, D. E., Guan, X., Yu, H., Shen, Z., Feng, Y., Frazier, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5027-5035.2002 · Cited by 430 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodNeuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397 · cited 3×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodResultKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 5×
“Together, this strengthens the classical view that VAN GLP-1Rs mainly mediate shortterm satiation and may be one of several redundant eating control mechanisms comprising the gut-brain axis (7,9,16,33).”
BackgroundMethodSelf-citationCentral and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes
Lenard, N. R., & Berthoud, H. (2008) · Obesity · doi:10.1038/oby.2008.511 · Cited by 338
Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318
Cooperation between brain and islet in glucose homeostasis and diabetes
Schwartz, M. W., Seeley, R. J., Tschöp, M. H., Woods, S. C., Morton, G. J., Myers, M. G., & D’Alessio, D. (2013) · Nature · doi:10.1038/nature12709 · Cited by 314
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodNakagawa, A., Satake, H., Nakabayashi, H., Nishizawa, M., Furuya, K., Nakano, S., Kigoshi, T., Nakayama, K., & Uchida, K. (2004) · Autonomic Neuroscience · doi:10.1016/j.autneu.2003.11.001 · Cited by 295 · cited 1×
“Vagal afferent neurons (VANs) express GLP-1 receptors (GLP-1Rs) (3,4) and terminate in the lamina propria of the intestinal mucosa as well as in the wall of the hepatic portal vein (HPV) (5).”
BackgroundNociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice
Stirling, C. L., Forlani, G., Baker, M. D., Wood, J. N., Matthews, E. A., Dickenson, A. H., & Nassar, M. A. (2005) · Pain · doi:10.1016/j.pain.2004.08.015 · Cited by 271 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodRüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · cited 5×
“As vagal lesion studies indicated that high levels of circulating GLP-1 can exert a VAN-independent effect (8,41), it is plausible that higher GLP-1 levels after the OGTT mask the role of VAN GLP-1Rs.”
BackgroundMethodSelf-citationCalanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251 · cited 1×
“First, an OGTT is thought to induce the release of GLP-1 with a different amplitude and/or time course than a solid meal ingested over several minutes (40).”
BackgroundPortal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
Balkan, B., & Li, X. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1449 · Cited by 200 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodScott, M. M., Williams, K. W., Rossi, J., Lee, C. E., & Elmquist, J. K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43703 · Cited by 190 · cited 4×
“26, not statistically significant (ns)] and (B) daily food intake [n = 11/11; ANOVA, group F(1,20) = 1.”
BackgroundMethodInfluentialSchjoldager, B. T. G., Mortensen, P. E., Christiansen, J., �rskov, C., & Holst, J. J. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540341 · Cited by 178 · cited 3×
“In addition, we demonstrated that VAN GLP-1R expression is necessary for the normal gastric emptying of a meal, as hypothesized from earlier studies (27,30,31), consistent with a paracrine effect of endogenous GLP-1 on VAN GLP-1Rs.”
BackgroundMethodResultGut Vagal Afferents Differentially Modulate Innate Anxiety and Learned Fear
Klarer, M., Arnold, M., Günther, L., Winter, C., Langhans, W., & Meyer, U. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0252-14.2014 · Cited by 159 · cited 3×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodSelf-citationCircadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell
Gil-Lozano, M., Mingomataj, E. L., Wu, W. K., Ridout, S. A., & Brubaker, P. L. (2014) · Diabetes · doi:10.2337/db13-1501 · Cited by 130
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124 · cited 1×
“It has long been hypothesized that VANs could control eating behavior by serving as a key mediator of nutritional cues from the intestine to the brain (6,7).”
BackgroundDeletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity
de Lartigue, G., Ronveaux, C. C., & Raybould, H. E. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.06.003 · Cited by 117 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodSensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
Ahrén, B. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00423.2003 · Cited by 99 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodA method for selective section of vagal afferent or efferent axons in the rat
Norgren, R., & Smith, G. P. (1994) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1994.267.4.r1136 · Cited by 90 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodHayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86 · cited 2×
“Moreover, unlike Sham-operated rats, SDA rats failed to show a GLP-1R–mediated incretin response (10).”
BackgroundMethodSelf-citationLabouesse, M. A., Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., & Pacheco‐López, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02364.x · Cited by 69 · cited 6×
“Finally, we measured food intake 30 min after an IP injection of CCK and found a 25–40% reduction (9,13) in both groups, demonstrating the preservation of VAN functional integrity (Fig.”
BackgroundMethodSelf-citationNishizawa, M., Nakabayashi, H., Uehara, K., Nakagawa, A., Uchida, K., & Koya, D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00565.2012 · Cited by 63 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodCirculating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms
Zhang, J., & Ritter, R. C. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00114.2011 · Cited by 62 · cited 1×
“As vagal lesion studies indicated that high levels of circulating GLP-1 can exert a VAN-independent effect (8,41), it is plausible that higher GLP-1 levels after the OGTT mask the role of VAN GLP-1Rs.”
BackgroundPPARγ in Vagal Neurons Regulates High-Fat Diet Induced Thermogenesis
Liu, C., Bookout, A. L., Lee, S., Sun, K., Jia, L., Lee, C., Udit, S., Deng, Y., Scherer, P. E., Mangelsdorf, D. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.021 · Cited by 61 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodSelf-citationKarimian Azari, E., Leitner, C., Jaggi, T., Langhans, W., & Mansouri, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074869 · Cited by 55 · cited 3×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodSelf-citationAbility of GLP-1 to decrease food intake is dependent on nutritional status
Ronveaux, C. C., de Lartigue, G., & Raybould, H. E. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.015 · Cited by 41 · cited 3×
“For food intake experiments after IP GLP-1, rats were fasted overnight and received a 3-g premeal 1 h before dark onset to allow GLP-1R trafficking to the VAN membrane (4).”
BackgroundMethodFujiwara, K., Gotoh, K., Chiba, S., Masaki, T., Katsuragi, I., Kakuma, T., & Yoshimatsu, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07563.x · Cited by 41
Anvari, M., Paterson, C. A., Daniel, E. E., & McDonald, T. J. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018863716749 · Cited by 41 · cited 2×
“In addition, we demonstrated that VAN GLP-1R expression is necessary for the normal gastric emptying of a meal, as hypothesized from earlier studies (27,30,31), consistent with a paracrine effect of endogenous GLP-1 on VAN GLP-1Rs.”
MethodResultSurina-Baumgartner, D. M., Langhans, W., & Geary, N. (1995) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1995.269.5.r978 · Cited by 40 · cited 1×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodSelf-citationGut-brain mechanisms controlling glucose homeostasis
Scarlett, J. M., & Schwartz, M. W. (2015) · F1000Prime Reports · doi:10.12703/p7-12 · Cited by 38
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Calik, M. W., Radulovacki, M. G., & Carley, D. W. (2014) · Journal of Visualized Experiments · doi:10.3791/52233 · Cited by 14 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodHepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
Proceedings of the 2012 Annual Meeting of the Society for the Study of Ingestive Behavior
(2012) · Appetite · doi:10.1016/j.appet.2012.05.003 · Cited by 9 · cited 6×
“68, ns], and (F) glucagon [n = 8/8; ANOVA; group F(1,14) = 0.”
BackgroundMethod
Research works printed but not linked: 1
- Arnold, 2012, Intraperitoneal (IP) glucagon-like peptide-1 (GLP-1) injections and meals in rats increase intestinal lymphatic GLP-1 similarly, Appetite, 59, e3
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Vagal afferent GLP-1 receptor knockdown accelerates gastric emptying [518] and vagal afferent denervation [795] or peripheral administration of exendin (9e 39) [794,795] blocks the effect of centrally or peripherally administered GLP-1 on gastric emptying.”
BackgroundSelf-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“5 418 – 420 This activation holds the ability to modulate food consumption by reducing food intake and conveying signals of satiety to the brain.”
BackgroundButyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit
Li, Z., Yi, C.-X., Katiraei, S., Kooijman, S., Zhou, E., Chung, C. K., Gao, Y., van den Heuvel, J. K., Meijer, O. C., Berbée, J. F. P., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314050 · Cited by 674
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Metadata
- Authors
- Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J.
- Affiliations
- ETH Zurich (CH)
- Corresponding author
- Krieger, Jean-Philippe
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-10-15
- Volume
- 65
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2180065345
- Cited by
- 269
- References
- 43
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 36 · 2023: 15 · 2022: 19 · 2021: 33 · 2020: 26 · 2019: 21 · 2018: 24 · 2017: 23 · 2016: 17 · 2015: 1
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- ETH Zurich (4712-2)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, vagal afferent neurons, nodose ganglion, gene knockdown, dietary intake, glycemia, insulin secretion, gastric emptying, meal size, energy homeostasis, enteroendocrine L cells
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Animals, Blood Glucose, Eating, Energy Metabolism, Gastric Emptying, Insulin, Intestines, Male, Neurons, Afferent, Nodose Ganglion, Vagus Nerve, Rats, Sprague-Dawley, Postprandial Period, Rats, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.